Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
Sylvie BoyerMaël BaudoinMarie Libérée NishimweMelina SantosMaud LemoineGwenaëlle MaradanBabacar SyllaCharles KouanfackPatrizia CarrieriAbbas MouradNicolas RouveauRaoul MohMoussa SeydiAlain AttiaMaame Esi WoodeKarine LacombePublished in: BMC health services research (2022)
Generic sofosbuvir/daclatasvir is very cost-effective for treating chronic hepatitis C in sub-Saharan Africa. Large-scale use of generics and an increase in national and international funding for hepatitis C treatment must be priorities for the HCV elimination agenda.